HC Wainwright Analysts Lower Earnings Estimates for RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Stock analysts at HC Wainwright reduced their Q1 2027 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a report issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.34). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2027 earnings at ($0.02) EPS, Q4 2027 earnings at $0.68 EPS and FY2027 earnings at $0.59 EPS.

Several other brokerages also recently issued reports on RYTM. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Telsey Advisory Group set a $143.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, March 12th. Morgan Stanley lowered their price objective on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, UBS Group reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.13.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM stock opened at $90.31 on Friday. Rhythm Pharmaceuticals has a one year low of $45.90 and a one year high of $122.20. The company’s 50-day moving average is $99.31 and its 200 day moving average is $102.60. The company has a market capitalization of $6.17 billion, a price-to-earnings ratio of -29.04 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. The firm had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company’s quarterly revenue was up 36.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) earnings per share.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Rhythm Pharmaceuticals by 39.2% in the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after acquiring an additional 1,407,313 shares during the period. RA Capital Management L.P. grew its stake in shares of Rhythm Pharmaceuticals by 17.3% during the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock valued at $713,618,000 after purchasing an additional 985,478 shares during the period. Alliancebernstein L.P. grew its stake in shares of Rhythm Pharmaceuticals by 1,493.8% during the 3rd quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after purchasing an additional 918,212 shares during the period. JPMorgan Chase & Co. increased its position in shares of Rhythm Pharmaceuticals by 445.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock valued at $49,513,000 after purchasing an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors bought a new position in shares of Rhythm Pharmaceuticals in the 3rd quarter worth approximately $60,417,000.

Insider Activity at Rhythm Pharmaceuticals

In related news, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer owned 160 shares in the company, valued at approximately $14,329.60. This trade represents a 97.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This trade represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,267 shares of company stock worth $2,719,955 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approved IMCIVREE for acquired hypothalamic obesity — the first and only approved therapy for this rare, hypothalamic-injury driven obesity indication, expanding the drug’s label and commercial opportunity. This approval is the primary bullish catalyst for RYTM today. Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE
• Positive Sentiment: Company management/earnings call transcript coverage highlights the FDA approval and likely commercial rollout plans, helping investors model revenue expansion from the new indication. RYTM Discusses FDA Approval of IMCIVIVREE Transcript
• Positive Sentiment: Some brokers still see sizable upside — a published broker composite shows a $133.19 price target for RYTM, signaling expectations for substantial post-approval value. This supports a bullish narrative for longer-term upside. Brokerages Set RYTM PT at $133.19
• Neutral Sentiment: HC Wainwright trimmed its price target to $100 (from $110) and reduced near-term EPS estimates but maintained a Buy rating — a mixed signal: recognition of the approval’s value but more conservative near-term modeling. HC Wainwright Lowers RYTM PT to $100
• Neutral Sentiment: Analyst/market commentaries reviewing valuation after recent share weakness note that long-term returns remain attractive but near-term volatility is high; useful context for investors deciding exposure size. A Look at RYTM Valuation
• Negative Sentiment: Bank of America issued a pessimistic forecast for RYTM, adding downside pressure from a major sell-side institution. Bank of America Issues Pessimistic Forecast
• Negative Sentiment: Royal Bank of Canada also published a pessimistic outlook, contributing to selling momentum from institutional channels. RBC Issues Pessimistic Forecast
• Negative Sentiment: Citizens JMP lowered expectations for RYTM, which may further pressure sentiment among trading-focused investors. Citizens JMP Lowers Expectations
• Negative Sentiment: Needham & Company reduced its outlook as well, adding to the cluster of downgrades that could cap upside despite the approval. Needham Lowers Expectations

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.